- Report
- June 2026
- 392 Pages
Global
From €5325EUR$5,850USD£4,588GBP
- Report
- April 2026
- 433 Pages
Global
From €7273EUR$7,990USD£6,266GBP
- Clinical Trials
- April 2026
- 280 Pages
Global
From €2731EUR$3,000USD£2,353GBP
- Report
- April 2026
- 981 Pages
Global
From €7273EUR$7,990USD£6,266GBP
- Report
- April 2026
- 328 Pages
Global
From €7273EUR$7,990USD£6,266GBP
- Report
- April 2026
- 280 Pages
Global
From €4551EUR$5,000USD£3,921GBP
- Drug Pipelines
- March 2026
- 150 Pages
Global
From €3413EUR$3,750USD£2,941GBP
- Report
- February 2026
- 200 Pages
Global
From €7273EUR$7,990USD£6,266GBP
- Report
- January 2026
- 220 Pages
Global
From €2276EUR$2,500USD£1,961GBP
- Report
- November 2025
- 200 Pages
Global
From €7237EUR$7,950USD£6,235GBP
- Report
- November 2025
- 200 Pages
Global
From €7237EUR$7,950USD£6,235GBP
- Report
- November 2025
- 200 Pages
Global
From €7237EUR$7,950USD£6,235GBP
- Report
- November 2025
- 200 Pages
Global
From €7237EUR$7,950USD£6,235GBP
- Drug Pipelines
- July 2025
- 280 Pages
Global
From €2731EUR$3,000USD£2,353GBP
- Report
- May 2026
- 180 Pages
Global
From €4324EUR$4,750USD£3,725GBP
- Report
- April 2026
- 195 Pages
Global
From €4324EUR$4,750USD£3,725GBP
- Report
- March 2026
- 200 Pages
Global
From €2539EUR$2,789USD£2,187GBP
- Report
- March 2026
- 200 Pages
Global
From €2539EUR$2,789USD£2,187GBP
- Report
- April 2026
- 135 Pages
Global
From €3640EUR$3,999USD£3,136GBP
- Report
- April 2026
- 136 Pages
Global
From €3640EUR$3,999USD£3,136GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more